Search
Acalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigational[L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically … To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: CALQUENCE® 100MGHexafluronium
go.drugbank.com/drugs/DB00941ApprovedIt is known to bind and block the activity of plasma cholinesterases. … Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery.
Synonyms: Hexamethylenebis(fluoren-9-yldimethylammonium)Lindane
go.drugbank.com/drugs/DB00431ApprovedWithdrawnIn Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical … Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment.
Categories: Compounds used in a research, industrial, or household settingSynonyms: γ-lindane, γ-HexachlorzyklohexanThioproperazine
go.drugbank.com/drugs/DB01622ApprovedIt is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes. … Thioproperazine is a potent neuroleptic with antipsychotic properties.
Categories: Heterocyclic Compounds, 3-Ring, Adrenergic alpha-1 Receptor AntagonistsSynonyms: N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine-2-sulfonamide, N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine-2-sulfonamideRopinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: REQUIP TABLET 1 mg, REQUIP TABLET 2 mgPaltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalPaltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth … hormone (GH) and decreases the production of growth-promoting insulin-like growth factor 1 (IGF-1).
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsTasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalTasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). … Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Synonyms: N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesFilgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigationalIn contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … [A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616]
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingObinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigationalObinutuzumab is a humanized anti-CD20 monoclonal antibody designed to treat B-cell malignancies. … [L54521] Like other drugs in its class, obinutuzumab targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes, mediating B-cell lysis.
Products: GAZYVA 1000 MG IV İNFÜZYONLUK KONSANTRE ÇÖZELTİ, 1 ADET, GAZYVA ® CONCENTRADO PARA SOLUCIÓN PARA INFUSIÓN 1000 MG / VIAL 40 MLCalaspargase pegol
go.drugbank.com/drugs/DB14730ApprovedInvestigationalSC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], [A40270]. … Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) [A40270].
Categories: L-asparaginase containing drugs, Compounds used in a research, industrial, or household setting